Clinical trials
Lung Cancer (Suspected or Confirmed) clinical trials
Below are recruiting lung cancer (suspected or confirmed) clinical trials, each written for real people, not researchers. We’re tracking 6,575 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07636148Recruiting
Registry of minimally invasive cancer treatment with advanced imaging
This study collects information from patients undergoing minimally invasive procedures to treat solid tumors (cancers) using advanced CT imaging guidance. Researchers want to understand how well this imaging technique helps doctors perform these procedures safely and effectively.
Lyon, Auvergne-Rhône-AlpesAges 18 years+ - NCT07189871RecruitingPhase 1/Phase 2
Targeted radiation therapy for advanced solid tumors
This study tests a new radioactive treatment (177Lu-BetaBart) for people with certain advanced solid tumors that have stopped responding to standard treatments. It aims to see if this targeted therapy can slow or stop tumor growth.
Dothan, AlabamaAges 18 years+ - NCT06047379RecruitingPhase 1/Phase 2
Testing NEO212 for brain tumors and metastases
This trial tests a new drug called NEO212 for people with certain brain tumors (like astrocytoma or glioblastoma) or cancer that has spread to the brain from other parts of the body. The goal is to see if it is safe and if it can help shrink or control the tumors.
Beverly Hills, CaliforniaAges 18 years+ - NCT04981119Recruiting
Test apheresis for CAR T manufacturing in HLA-A2 solid tumors
This trial studies how a process called apheresis is used to make CAR T cells for people with certain solid tumors. It is designed for tumors that have lost a specific immune marker (HLA-A*02), which may affect how well CAR T therapies work.
Gilbert, ArizonaAges 18 years+ - NCT05426135Recruiting
AI tool to assess cancer risk and guide care
This study tests an artificial intelligence (AI) system that uses your health information and medical images to better judge cancer risk and support diagnosis and treatment decisions. It may help doctors make more consistent assessments by combining clinical records, imaging, and other lab-style data.
Wuhan, HubeiAges 18–75 - NCT06653478Recruiting
Smarter cancer risk assessment using all your medical info
This study is testing a new way to use medical images, records, and other information to better assess cancer risk and guide treatment. It may be a good fit if you have a suspicious spot in your lungs, stomach, or colon, or if you are healthy and want to help with early cancer detection research.
Wuhan, HubeiAges 18–75 - NCT07623369RecruitingPhase 1
First-in-Human Study of HH160 for Advanced Solid Tumors
This is an early-stage trial testing a new drug called HH160 in patients with advanced cancer (solid tumors). Researchers want to find the right dose and learn how well it works and what side effects it causes.
Waratah, New South WalesAges 18–75 - NCT06769126RecruitingPhase 2
Personalized treatment study for extensive stage small cell lung cancer
This study uses biomarker tests on your tumor to find a personalized treatment after initial chemotherapy. You will be assigned to one of four treatment groups based on your biomarker results.
Loma Linda, CaliforniaAges 18 years+ - NCT00900419Recruiting
Check biomarkers during bronchoscopy in breathing and throat pre-cancer
This study looks at “biomarkers” (measurable signals in samples) taken during bronchoscopy or related procedures in people with severe airway pre-cancer or certain lung/throat cancers, and in healthy volunteers. The goal is to better understand what these biomarkers mean and how they might help with diagnosis, staging, or monitoring.
Aurora, ColoradoAges 21–90 - NCT07153055RecruitingPhase 1/Phase 2
Lurbinectedin with osimertinib for transformed small cell lung cancer
This trial tests a combination of two drugs—lurbinectedin and osimertinib—for people whose lung cancer started as EGFR-mutated non-small cell lung cancer but has changed into small cell lung cancer. The goal is to see if this combination can help control the cancer.
Indianapolis, IndianaAges 18 years+ - NCT05375591Recruiting
AI study to sort lung nodules after past cancer treatment
This study uses computer tools (AI) and detailed scan patterns to better classify new lung nodules in people who previously had curative-intent cancer treatment. It may help doctors decide whether a nodule is likely benign or cancer, using your CT scan and related medical history.
LondonAges 18 years+ - NCT03742687Recruiting
Testing a shorter, stronger radiation schedule for lung cancer
This trial studies a different way to deliver radiation to people with locally advanced, non-operable non-small cell lung cancer. It may help by aiming to treat the tumor effectively with a different radiation timing and dose pattern.
AarhusAges 18 years+ - NCT06492421RecruitingPhase 2
Immunotherapy before surgery for lung cancer
This trial tests whether giving two immunotherapy drugs directly into the tumor before surgery can shrink non-small cell lung cancer and improve outcomes. It is for people with early-stage (IIIA) lung cancer who are candidates for surgery.
Guanzhou, GuangdongAges 18–75 - NCT07761910RecruitingPhase 2
Study of heart effects of radiation therapy using PET-CT for stage III lung cancer
This study looks at whether PET-CT scans can help detect heart damage caused by radiation therapy in patients with stage III lung cancer. If you're getting chemotherapy and radiation together, you may participate to help doctors find ways to reduce heart risks.
Indianapolis, IndianaAges 18 years+ - NCT07680764RecruitingPhase 2
Imzokitug plus pumitamig and chemo for first-line advanced lung cancer
This trial tests a new combination of drugs (imzokitug, pumitamig, and platinum-doublet chemotherapy) as a first treatment for advanced or metastatic non-small cell lung cancer that has not spread to the brain. The goal is to see if adding imzokitug makes the standard treatment work better.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06667154RecruitingPhase 2
Low-dose nivolumab plus chemo for early lung cancer
This trial tests a lower dose of the immunotherapy drug nivolumab (Opdivo) combined with standard chemotherapy before surgery for patients with early-stage non-small cell lung cancer (NSCLC). The goal is to see if this combination shrinks the tumor and improves outcomes with fewer side effects.
São José do Rio Preto, São PauloAges 18 years+ - NCT07632365RecruitingPhase 1/Phase 2
Immunotherapy plus chemoradiation for inoperable stage III lung cancer
This trial tests a new combination of immunotherapy and chemotherapy before and after standard chemoradiation for patients with stage III lung cancer that cannot be surgically removed. The goal is to see if this approach improves outcomes compared to chemoradiation alone.
Shanghai, XuhuiAges 18 years+ - NCT06728865RecruitingPhase 2
Furmonertinib plus Avastin for EGFR+ lung cancer with brain mets
This trial tests a combination of two targeted drugs (Furmonertinib and Avastin) as the very first treatment for people with a specific type of lung cancer (EGFR-mutant non-small cell) that has spread to the brain. The goal is to see how well it works and how safe it is.
Guangzhou, GuangdongAges 15–75 - NCT07545954RecruitingPhase 1
DSP-0390 plus Atezolizumab for Small Cell Lung Cancer
This trial tests a new drug called DSP-0390 combined with atezolizumab (an immunotherapy) in patients with small cell lung cancer who have already completed initial chemotherapy treatment. The goal is to see if this combination can help prevent the cancer from coming back or growing.
St Louis, MissouriAges 18 years+ - NCT06755684RecruitingPhase 2
Pre-surgery targeted drug combo for EGFR-mutant lung cancer
This trial tests a new targeted pill (befotertinib) given before surgery, either with another targeted drug (bevacizumab) or with standard chemotherapy. The goal is to shrink the tumor and improve outcomes for people with a specific type of lung cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07508852RecruitingPhase 1/Phase 2
PET scan for small cell lung cancer diagnosis
This study uses a special PET scan (68Ga-PFD3) to take pictures of small cell lung cancer tumors. The goal is to see if this scan can help doctors better diagnose and evaluate the cancer, which may guide treatment decisions.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07408635RecruitingPhase 2
New Immunotherapy Plus Chemotherapy Before Lung Cancer Surgery
This trial tests a new combination of an immunotherapy drug (IBI363) plus chemotherapy before surgery in people with Stage III lung cancer that can't be removed at first. The goal is to shrink the tumor so it can be surgically removed.
ShanghaiAges 18 years+ - NCT05477979Recruiting
Study how stress affects lung cancer treatment outcomes
This study looks at whether psychological stress changes how well lung cancer treatments work and what the outlook is. You may qualify if you’re about to start (or recently started) certain immunotherapy-based treatments, and you can complete stress and well-being questionnaires.
Changsha, HunanAges 18 years+ - NCT07355205RecruitingPhase 1/Phase 2
Combination immunotherapy for advanced lung cancer
This trial tests a three-drug combination (ipilimumab, nivolumab, and nogapendekin alfa inbakicept) as a first treatment for people with stage IV or recurrent non-small cell lung cancer. The goal is to see if this approach can help your immune system fight the cancer more effectively.
St Louis, MissouriAges 18 years+
Hear when a new Lung Cancer (Suspected or Confirmed) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer (suspected or confirmed)?
- Yes. Clin2 currently lists 6,575 recruiting lung cancer (suspected or confirmed) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer (suspected or confirmed) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer (suspected or confirmed) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.